What is the recommended treatment for myasthenia gravis?

Myasthenia Gravis Treatment

For myasthenia gravis, treatment should be initiated with pyridostigmine (starting at 30 mg PO three times daily, titrating up to a maximum of 120 mg four times daily) as first-line symptomatic therapy, followed by corticosteroids (prednisone 1-1.5 mg/kg PO daily) for patients requiring immunosuppression, with consideration of thymectomy in younger acetylcholine receptor antibody-positive patients, and escalation to IVIG (2 g/kg over 5 days) or plasmapheresis for severe or refractory cases.

Treatment Algorithm by Disease Severity

Moderate Disease (Grade 2)

• Consult neurology immediately - all grades warrant specialist evaluation given the risk of respiratory compromise 1
• Start pyridostigmine 30 mg PO three times daily, gradually increasing based on symptom response to maximum 120 mg four times daily 1
• If inadequate response to pyridostigmine alone, initiate corticosteroids (prednisone 1-1.5 mg/kg PO daily) and wean based on symptom improvement 1
• Monitor pulmonary function with negative inspiratory force and vital capacity 1

Severe Disease (Grade 3-4) or Myasthenic Crisis

• Permanently discontinue any immune checkpoint inhibitors if applicable 1
• Admit to hospital with ICU monitoring capability 1
• Continue corticosteroids AND initiate either:
  • IVIG 2 g/kg over 5 days, OR
  • Plasmapheresis for 5 days 1
• Perform frequent pulmonary function assessments and daily neurologic evaluations 1

Essential Diagnostic Workup

Before initiating treatment, obtain:

• Acetylcholine receptor (AChR) antibodies - if negative, test for muscle-specific kinase and lipoprotein-related protein 4 antibodies 1
• Pulmonary function tests with negative inspiratory force and vital capacity 1
• CPK, aldolase, ESR, CRP to evaluate for concurrent myositis 1
• Electrodiagnostic studies including repetitive nerve stimulation and/or single-fiber EMG 1
• If respiratory insufficiency or elevated CPK/troponin: ECG and echocardiogram to rule out myocarditis 1

Long-Term Immunosuppressive Strategy

For patients requiring chronic immunosuppression beyond initial corticosteroids:

• Azathioprine is a first-line steroid-sparing agent 2
• Thymectomy should be considered in younger patients with acetylcholine receptor antibody-positive MG, as post-hoc analysis shows 52% steroid-free remission rates 3
• For refractory cases, newer targeted therapies including complement inhibitors and neonatal Fc receptor antagonists are available 4, 5

Critical Medication Avoidance

Avoid medications that worsen myasthenia 1:

• β-blockers
• IV magnesium
• Fluoroquinolones
• Aminoglycosides
• Macrolides

This is essential to prevent myasthenic crisis, particularly in patients with clinical myasthenia or positive anti-acetylcholine receptor antibodies 6.

Treatment Subgroup Considerations

The approach should be modified based on antibody status:

• Early-onset AChR+ MG: Consider thymectomy early 2
• MuSK antibody-positive MG: May respond differently to standard therapies; avoid pyridostigmine if ineffective 2
• Ocular MG: May require less aggressive immunosuppression initially 2
• Late-onset MG: Higher threshold for thymectomy 2

Monitoring and Follow-Up

• Baseline chest CT 3-4 months after any surgical intervention 6
• For completely resected stage I/II thymomas: CT annually for 5 years, then every 2 years 6
• Continue surveillance for 10-15 years given risk of late relapses 6
• Monitor for secondary autoimmune disorders and educate patients about myasthenic crisis triggers 6

Key Clinical Pitfalls

The evidence provided focuses heavily on immune checkpoint inhibitor-associated myasthenia gravis [1-1], which represents a specific subset with more aggressive management protocols. However, the core treatment principles apply to all MG cases: early recognition of respiratory compromise risk, prompt initiation of symptomatic therapy, and escalation to immunosuppression when needed. The critical distinction is that checkpoint inhibitor-associated MG may be monophasic and not require long-term immunosuppression 1, whereas idiopathic MG typically requires chronic management 5, 2.